Vanguard Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-2,324,392
| Closed | -$3.7M | – | 4505 |
|
|
2024
Q1 | $3.7M | Sell |
2,324,392
-446,182
| -16% | -$662K | ﹤0.01% | 3407 |
|
|
2023
Q4 | $2.38M | Buy |
2,770,574
+9,472
| +0.3% | +$8.32K | ﹤0.01% | 3543 |
|
|
2023
Q3 | $2.95M | Sell |
2,761,102
-32,158
| -1% | -$66.5K | ﹤0.01% | 3461 |
|
|
2023
Q2 | $7.23M | Sell |
2,793,260
-885,263
| -24% | -$3.16M | ﹤0.01% | 3126 |
|
|
2023
Q1 | $15M | Sell |
3,678,523
-810,626
| -18% | -$3.75M | ﹤0.01% | 2734 |
|
|
2022
Q4 | $22.5M | Buy |
4,489,149
+589,852
| +15% | +$3.7M | ﹤0.01% | 2561 |
|
|
2022
Q3 | $51M | Buy |
3,899,297
+496,089
| +15% | +$7.51M | ﹤0.01% | 2172 |
|
|
2022
Q2 | $43.6M | Buy |
3,403,208
+388,733
| +13% | +$5.38M | ﹤0.01% | 2261 |
|
|
2022
Q1 | $46M | Buy |
3,014,475
+47,238
| +2% | +$737K | ﹤0.01% | 2343 |
|
|
2021
Q4 | $52.6M | Buy |
2,967,237
+1,407,112
| +90% | +$27M | ﹤0.01% | 2318 |
|
|
2021
Q3 | $32.8M | Buy |
1,560,125
+171,051
| +12% | +$3.77M | ﹤0.01% | 2595 |
|
|
2021
Q2 | $27.4M | Sell |
1,389,074
-852,374
| -38% | -$20M | ﹤0.01% | 2679 |
|
|
2021
Q1 | $65.2M | Buy |
2,241,448
+485,187
| +28% | +$13.6M | ﹤0.01% | 2166 |
|
|
2020
Q4 | $53.2M | Buy |
1,756,261
+309,724
| +21% | +$6.78M | ﹤0.01% | 2170 |
|
|
2020
Q3 | $23M | Buy |
1,446,537
+37,558
| +3% | +$685K | ﹤0.01% | 2391 |
|
|
2020
Q2 | $27.8M | Buy |
1,408,979
+934,972
| +197% | +$17.9M | ﹤0.01% | 2270 |
|
|
2020
Q1 | $5.84M | Buy |
474,007
+14,298
| +3% | +$233K | ﹤0.01% | 2904 |
|
|
2019
Q4 | $8.5M | Buy |
459,709
+288,165
| +168% | +$4.21M | ﹤0.01% | 2935 |
|
|
2019
Q3 | $2.38M | Buy |
171,544
+3,695
| +2% | +$55.5K | ﹤0.01% | 3395 |
|
|
2019
Q2 | $2.46M | Buy |
+167,849
| New | +$2.46M | ﹤0.01% | 3414 |
|
Vanguard Group's NGM Position: Q2 2024 in Review
Vanguard Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 2,324,392 shares — an estimated $3.7M sold.
Vanguard Group first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $65.2M in Q1 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Vanguard Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Vanguard Group sold 2,324,392 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $3.7M.
- Vanguard Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Vanguard Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $65.2M in Q1 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.